Navigation Links
ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal
Date:10/7/2008

EMERYVILLE, Calif., Oct. 7 /PRNewswire/ -- ProGenTech Limited, a life sciences & diagnostics company based in Shanghai, China and Emeryville, CA has signed a licensing agreement with Human Genetic Signatures, a Sydney, Australia based life science company to gain access to key hospital-acquired infection targets, payment terms were not disclosed.

Under the terms of the agreement, Human Genetic Signatures will develop assays for MRSA, MSSA, VRE and C. difficile which will then be further integrated into the ProGenTech Entura platforms. It is anticipated that manual assays for these initial targets will be taken to the FDA during 2009 followed by fully integrated and automated versions of the assays in 2010. Launching these assays will mark ProGenTech's initial foray into the molecular diagnostics market.

Dr. Trevor Hawkins, the Chairman & CEO of ProGenTech said, "We are very excited to be working with Human Genetic Signatures to develop and commercialize these assays. The advantages of our 'Press play and walk away(TM)' Entura systems together with the Human Genetic Signatures' 3base(TM) simplification technology will provide a valuable solution to the underserved hospital-acquired infections market."

"Our 3base(TM) assay technology is a natural fit with the current and future Entura systems," said Angus Hastie, CEO of Human Genetic Signatures. "Market trends are indicating that fast and easy to use modular platforms are a powerful path forward for molecular diagnostics. ProGenTech's platform vision in concert with a menu empowered by 3base(TM) assays will deliver new clinical benefits and the complete diagnostics package to this burgeoning market."

The key advantage of ProGenTech's Entura platforms is that they greatly reduce the total hands on time historically associated with sample preparation. The Entura uses a unique cassette-based approach in which all reagents for RNA, DNA or protein applications are pre-loaded in the casset
'/>"/>

SOURCE ProGenTech Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. ProGenTech Completes $21 Million Series C Financing
2. ProGenTech Limited Appoints Executive Management Team
3. U.S. Health Initiative Targets Aging Hispanics
4. Global Health Project targets reducing AIDS among Indias adolescents
5. GP targets on heart disease should be simpler and based more on treatment and prevention
6. International Law Enforcement Operation Targets Underground Manufacture of Anabolic Steroids
7. OralLongevity (TM) Program Targets Oral Health of Older Americans
8. AWWA Water 101 Seminar Targets Sales, Marketing and PR Pros
9. Combination targets: some drugs may work best when they work together
10. Targets on the horizon: Emerging therapies and novel targets
11. Anti-smoking strategy targets fourth-graders, parents in rural and urban Georgia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...rchers find long-term risks, but not all agree , ...ing sinuses with a saline solution might have soot...ke you more prone to infections in the long run by..., "By washing the nose, we are removing the bad...e good mucus that contains the antimicrobial agent...
(Date:11/9/2009)... Industry leader readies its a...lly migrate to and reduce IT risk on Windows 7 and... plans with solution readiness. , ..., , , ,News Facts ,   As businesses ...indows 7 and Windows 2008 Server R2, Lumension , ...
(Date:11/9/2009)... NBC’s Today Show featur...ian, Dr. Jill Waibel on Friday Nov. 6th 2009, The... Berns after their first appearance on the Today S...d by Matt Lauer regarding their treatments by Dr. ...Pulse TotalFX laser. , (P...
(Date:11/9/2009)... This device is ideal for endu...t and is available at ShopCompex.com , ...09 -- Compex®, a brand of DJO Incorporated, a ...s, is pleased to announce the launch of the latest...Compex Sport Elite. The Sport Elite was designed t...
(Date:11/9/2009)... Vancouver Career College laun... Surrey, BC (Vocus) November 9...er College in Surrey are digging through their clo... Surrey citizens to do the same in order to help w...ay we focus on building a community here on campus...
Breaking Medicine News(10 mins):Health News:Sinus Rinses May Do More Harm Than Good 2Health News:Sinus Rinses May Do More Harm Than Good 3Health News:Lumension Provides Enhanced Endpoint Protection and Support for The Latest Windows Platforms 2Health News:Lumension Provides Enhanced Endpoint Protection and Support for The Latest Windows Platforms 3Health News:Lumension Provides Enhanced Endpoint Protection and Support for The Latest Windows Platforms 4Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 2Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 3Health News:Lumenis Ultrapulse TotalFX Featured for the Treatment of Burn Scars on the Today Show 4Health News:COMPEX Intoduces New Sport Elite Electrical Muscle Stimulation Unit 2Health News:COMPEX Intoduces New Sport Elite Electrical Muscle Stimulation Unit 3Health News:Surrey College Students Collect Clothing for Women and Children 2
...ificial heart was approved by the U.S. Food and Dr...al heart has been approved for patients with sever...plant. Under the FDA's Humanitarian Use Device... per year. The usage of this artificial heart is r...
... about 300 million poultry next month against bird...ls in the midst of large-scale criticism over the ...nced that the government plans of mass vaccination...rged Jakarta to give precedence for controlling th...
...em that could help in determining the condition of...do Silvio Nu?o Almirantearena has developed a new ...rt attack, brain stroke or high blood pressure, by...agnosis of the condition of the arterial system in...
...of Clinical Investigation and the September issue ... Monash University have reported that a new drug h...nd heart attacks by improving the blood flow in di... of the arteries. The finding is a significa...
... Zero after 9/11 are struggling with serious healt...to advocates.// "When we were needed on 9/11, no o...re anymore," said Lucelly Gil, who was present in ... necessary protection. "All of us who worked in th...
...t it has asked EU health authorities to re-examine...reatment Tarceva.// The European Committee for Me... rejected the Tarceva application. "People wi...ady been approved for this indication in the US," ...
Other Medicine News:Health News:First Implantable artificial heart gets FDA’s approva 2Health News:Indonesia To Conduct Mass Vaccination Of Poultry 2Health News:A New System Developed For Studying The Condition Of The Human Arterial System 2Health News:A New Drug That Could Revolutionize Management Of Heart Disease 2
(Date:11/6/2009)..., BOTHELL, Wash., Nov. 6 /PRNewswire-FirstCall/ -...financial results for the three and nine months en... SCOLR Pharma,s President and CEO, said, "We conti...r 12-hour ibuprofen formulation. Several potential...time, personnel and external resources as they eva...
(Date:11/6/2009)..., ,, FORT WASHINGTON, Pa., Nov. 6 /PRNewsw...g Administration (FDA), McNeil Consumer Healthcare...luntary recall of a limited number of product lots...bottles, with the distinctive red EZ-OPEN CAP. McN...uncharacteristic smell or taste associated with th...
(Date:11/6/2009)..., MORRISTOWN, N.J., Nov. 6 /PRNewswire-FirstCall/...leading specialty pharmaceutical company, announce...hief executive officer, will provide an overview a...Suisse 18th Annual Healthcare Conference on Wednes...d Time. ,, This presentation will be webcast li...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Avalere Estimates Medicare Part D Donut Hole Will Be Obsolete in 2023 50579 1Avalere Estimates Medicare Part D Donut Hole Will Be Obsolete in 2023 50579 2Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 1Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 2Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 3Materials and Processes for Medical Devices Event Brings Clinicians Engineers Designers Together 50574 4Lung Cancer Alliance Praises Congresswoman Donna Christensen for Introduction of Legislation to Correct Healthcare Disparities 50569 1Lung Cancer Alliance Praises Congresswoman Donna Christensen for Introduction of Legislation to Correct Healthcare Disparities 50569 2
...s, a division of Wyeth (NYSE: WYE ), announced to...A) has issued an approvable letter for,the first-i...e treatment of,adult patients with community-acqui...he FDA requested that Wyeth provide,additional ana...L for the,treatment of patients with CAP with illn...
...development in treatment-experi...Mune, Inc.,(Nasdaq: ITMN ) today announced that i...evaluating ITMN-191, designated R7227 at Roche (SW...interferon alpha-2a) and,Copegus(R) (ribavirin) in...patitis C virus (HCV) genotype 1 infection., Inte...
Other Medicine Technology:Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 2Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 3Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 4Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 5Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 6InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 2InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 3InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C 4
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: